Highest-materiality recent filing
Caribou Q2 2026 net loss $24.3M; vispa-cel and CB-011 show strong efficacy data
Q2 2026 net loss $24.3M ($0.24/share) vs $54.1M ($0.58) in Q2 2025, which included $21.3M impairment.
Caribou Biosciences shareholders reject officer exculpation amendment at annual meeting
Proposal 3 (officer exculpation) failed: 37.5M for, 3.5M against, 27.1M broker non-votes.
Caribou reports vispa-cel 82% ORR, 17.1mo mPFS in 2L LBCL; CB-011 83% CR rate in MM
Vispa-cel in 27 optimized 2L LBCL patients: 82% ORR, 67% CR, 17.1 months median PFS.
Caribou Q1 2026 rev flat at $2.4M; FDA aligns on pivotal trial for vispa-cel
FDA alignment on ANTLER-3 pivotal phase 3 trial for vispa-cel in 2L LBCL; primary endpoint PFS, crossover allowed.
Caribou gets RMAT designation from FDA for CB-011 in relapsed/refractory multiple myeloma
FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for CB-011 allogeneic anti-BCMA CAR-T.
Caribou Biosciences FY2025 net loss $148.1M; cash $142.8M funds into 2H 2027
GAAP net loss FY2025 $148.1M ($1.59/sh) vs $149.1M ($1.65) prior year; non-GAAP loss $126.8M excluding $21.3M impairment.
Caribou Biosciences reports Q3 2025 clinical data: vispa-cel 86% ORR, CB-011 92% ORR; cash $159.2M
Vispa-cel ANTLER phase 1: 86% ORR, 63% CR, 53% PFS at 12mo in 35 patients with optimized profile (≥2 HLA match, young donor).
Caribou reports positive vispa-cel phase 1 data: 82% ORR, 64% CR in 2L LBCL; cash ~$159.2M
Vispa-cel confirmatory cohort (N=22): 82% ORR, 64% CR rate, 51% 12-month PFS in 2L LBCL.
Caribou Q2 net loss $54.1M ($0.58/sh); clinical data on track for H2 2025
GAAP net loss $54.1M ($0.58/sh) vs $37.7M ($0.42/sh) in Q2 2024; non-GAAP loss $32.8M ($0.35/sh) excluding $21.3M impairment.
Caribou Biosciences regains Nasdaq minimum bid price compliance after 10-day period above $1.00
Received Nasdaq compliance notice on June 18, 2025, confirming regained compliance with Listing Rule 5450(a)(1).
Caribou Biosciences stockholders approve reverse stock split authorization at annual meeting
Class I directors elected: Scott Braunstein (40.2M votes for) and Ran Zheng (30.4M votes for).
Caribou Q1 net loss $40M; cuts 32% workforce, extends cash runway into H2 2027
Cash, equivalents & securities $212.5M as of Mar 31, 2025 (down from $249.4M at Dec 31, 2024).
Caribou cuts 32% workforce, discontinues lupus/AML trials, cash runway to H2 2027
Workforce reduction of 47 employees (~32%), expected completion by Q2 2025.
Caribou Biosciences Q4/FY2024 net loss $149.1M; cash $249.4M into H2 2026; CSO retiring
Net loss $149.1M in 2024 vs $102.1M in 2023; revenue fell to $10.0M from $34.5M on AbbVie deal end.
Caribou Biosciences initiates lupus trial, plans 2025 data milestones, hires new CFO
Initiated GALLOP Phase 1 trial of CB-010 in lupus nephritis and extrarenal lupus; FDA Fast Track for refractory SLE.
Caribou Biosciences appoints Sri Ryali as CFO, effective January 2, 2025
Sri Ryali named CFO; brings 20 years biopharma finance experience; most recently CFO of Codexis.
Caribou Q3 net loss $34.7M vs $10.0M YoY; cash $281M funds into H2 2026
Revenue $2.0M, down from $23.7M due to AbbVie termination; R&D expense $30.4M.
Caribou Biosciences appoints Ryan Fischesser interim CFO and grants 25,000 RSUs
Ryan Fischesser designated interim principal financial officer and accounting officer effective Sept 27, 2024, following Jason O'Byrne's resignation.
CFO Jason O'Byrne resigns effective Sept 27; Ryan Fischesser named principal accounting officer
Jason O'Byrne resigns as CFO effective Sept 27, 2024, to pursue other opportunity; no disagreement with company.
Caribou Biosciences appoints Tina Albertson, MD PhD, as Chief Medical Officer
Dr. Albertson brings 15 years of experience in cellular therapy development, most recently as CMO at Lyell Immunopharma.
Caribou Q2 net loss $37.7M; extends cash runway to H2 2026 after 12% workforce cut
Net loss $37.7M in Q2 2024 vs $29.5M in Q2 2023; cash & equivalents $311.8M at June 30, down from $372.4M.
Caribou discontinues CAR-NK platform, cuts 12% workforce to extend cash runway into H2 2026
Preliminary cash $311.8M at June 30, 2024; expects to report Q2 results later.
Caribou Biosciences stockholders elect three directors and ratify auditor at 2024 annual meeting
Elected Class III directors: Rachel Haurwitz (57.4M for), Dara Richardson-Heron (50.2M for), Natalie Sacks (50.2M for).
Caribou Biosciences reports CB-010 ANTLER Phase 1 data: 14.4 mo median PFS with partial HLA matching
Median PFS of 14.4 months with ≥4 HLA matches (N=13) vs 2.8 months with ≤3 matches (N=33).
Caribou Q1 net loss $41.2M; cash $345.9M; IND cleared for CB-010 in lupus
Net loss of $41.2M for Q1 2024 vs $28.0M in Q1 2023; R&D expenses rose to $33.8M.
FDA cleared IND for CB-010 (allogeneic anti-CD19 CAR-T) to treat lupus nephritis and extrarenal lupus.
Caribou Biosciences reports FY 2023 net loss $102.1M, cash $372.4M; clinical updates
Net loss $102.1M in FY 2023 vs $99.4M in FY 2022; R&D expenses rose to $112.1M.
Caribou appoints Tim Kelly as CTO; plans CB-010 pivotal trial by YE 2024, cash into Q4 2025
Tim Kelly appointed CTO; previously CEO of Oxford Biomedica Solutions, led technical ops at Sarepta, Shire, and Biogen.
Caribou Biosciences CMO Syed Rizvi to leave Dec 31, 2023; severance terms set
Dr. Rizvi's departure effective Dec 31, 2023; previously announced Dec 12, 2023.
Caribou reaches FDA alignment on CB-010 phase 3 trial design; CMO to depart Dec 31
FDA accepts comparator arm of platinum-based immunochemotherapy + HDCT + ASCT for CB-010 phase 3 in 2L r/r LBCL.
Caribou Biosciences Q3 net loss $10M, cash $396.7M; pipeline advances with CB-010, CB-011, CB-012
Net loss of $10.0M for Q3 2023 vs $26.6M in Q3 2022; revenue $23.7M (incl. $21.5M from AbbVie termination).
Caribou Biosciences gets FDA IND clearance for CB-012 allogeneic CAR-T in r/r AML
FDA cleared IND for CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for relapsed/refractory AML.
AbbVie exercised termination for convenience, citing strategic focus; not related to Caribou's performance or data.
Caribou Q2 net loss $29.5M; CB-010 shows 94% ORR; cash runway into Q4 2025
Net loss of $29.5M for Q2 2023 versus $26.7M in Q2 2022; R&D expenses $26.5M.
Caribou Biosciences prices upsized $125M public offering at $6.50/sh
Priced 19,230,769 shares at $6.50 per share; underwriters granted 30-day option for 2,884,615 additional shares.
Caribou announces positive long-term follow-up from ANTLER Phase 1 of CB-010
Positive long-term follow-up results from dose escalation portion of ANTLER Phase 1 trial.
Caribou announces positive long-term follow-up for CB-010 in ANTLER Phase 1
Positive long-term follow-up results from dose escalation of ANTLER Phase 1 for CB-010 in relapsed/refractory B-NHL.
CB-010 Phase 1 data: 94% ORR, 69% CR in r/r B-NHL; 44% CR ≥6 months; cash ~$292.5M
CB-010 achieved 94% ORR (15/16) and 69% CR (11/16) in r/r B-NHL patients in ANTLER Phase 1 dose escalation.
Pfizer invests $25M in Caribou at $5.33/sh; gains SAB seat & BCMA first negotiation rights
Pfizer purchased 4,690,431 shares at $5.33/sh for ~$25M; deal closed June 30, 2023.
Andrew Guggenhime: 31.0M votes for, 5.3M withheld, 9.4M broker non-votes.
Caribou Q1 net loss $28M, cash $291M; CB-010 dose expansion enrolling, CB-011 dosing initiated
Net loss of $28.0M in Q1 2023, vs $19.1M in Q1 2022, driven by higher R&D expenses.
Caribou Biosciences gets FDA Fast Track for CB-011 CAR-T in relapsed/refractory multiple myeloma
CB-011 is an allogeneic anti-BCMA CAR-T with immune cloaking (B2M-HLA-E transgene).
Caribou initiates dose expansion of CB-010 ANTLER trial in second-line LBCL patients
CB-010 is first allogeneic CAR-T evaluated in second-line LBCL, per company.
Caribou Biosciences doses first patient in Phase 1 trial of CB-011 for multiple myeloma
First patient dosed with CB-011 at dose level 1 (50x10^6 CAR-T cells) in CaMMouflage Phase 1 trial for relapsed/refractory multiple myeloma.
Caribou Biosciences schedules 2023 annual meeting for June 15, 2023
Annual meeting will be held virtually on June 15, 2023 at 7:30 a.m. PDT.
Caribou Q4 net loss $27M; cash $317M; CB-010 data update planned H2 2023
Net loss of $27.0M in Q4 2022 and $99.4M for full year 2022, vs. $18.5M and $66.9M in 2021.
Caribou appoints CFO Jason O'Byrne as principal accounting officer; controller Fischesser cedes role
Jason V. O'Byrne, CFO, appointed principal accounting officer effective Dec 15, 2022.
Caribou: 12-month CB-010 data shows durable CR in 2/6; selects ROR1 for CB-020
CB-010 ANTLER cohort 1: 6/6 CR best response; 3/6 durable CR at 6 months; 2/6 maintain CR at 12 months; longest CR 18 months.
Caribou Bio receives RMAT and Fast Track designations from FDA for CB-010 CAR-T therapy
FDA grants RMAT for relapsed/refractory large B cell lymphoma (LBCL) and Fast Track for r/r B-NHL for CB-010.
CB-011 is a genome-edited allogeneic anti-BCMA CAR-T cell therapy with immune cloaking.
On January 2, 2025, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), announced the appointment of Sriram Ryali, age 44, to the position of Chief Financial Officer (“CFO”) of the Company, effective as of January 2, 2025 (the “Start Date”).
On September 23, 2024, Caribou Biosciences, Inc. (the “Company”) designated Ryan Fischesser, the Company’s current Vice President of Finance and Controller, as the Company’s interim principal financial officer and interim principal accounting officer, effective as of 5:00 p.m. Pacific time on September 27, 2024.
Mr. O’Byrne serves as the Company’s principal financial officer and principal accounting officer through September 27, 2024, his final day with the Company.
On September 1, 2024, Jason O’Byrne, the Chief Financial Officer of Caribou Biosciences, Inc. (the “Company”), informed the Company of his intent to resign from his position, effective September 27, 2024, to pursue another opportunity.
The Company intends to appoint Ryan Fischesser, the Company’s current Vice President of Finance and Controller, to assume the role of the Company’s principal accounting officer, effective as of the close of business on September 27, 2024.
As previously announced on December 12, 2023, Syed Rizvi, M.D., the Chief Medical Officer of Caribou Biosciences, Inc. (the “Company”), will be leaving the Company effective December 31, 2023.
Syed Rizvi, M.D., the Chief Medical Officer of Caribou Biosciences, Inc. (the “Company”), will be leaving the Company effective December 31, 2023.
The Company’s Vice President of Finance and Controller, Ryan Fischesser, who was previously serving as the Company’s principal accounting officer, will continue serving as the Company’s Vice President of Finance and Controller but not as the Company’s principal accounting officer, effective as of December 15, 2022.
On December 15, 2022, Caribou Biosciences, Inc. (the “Company”) appointed Jason V. O’Byrne, its Chief Financial Officer, as the Company’s principal accounting officer.
increased the size of the Board from seven to eight directors and unanimously agreed to extend an offer to David L. Johnson, M.B.A., to serve as a Class II director of the Company.
On November 4, 2021, the Board of Directors (the “Board”) of Caribou Biosciences, Inc., a Delaware corporation (the “Company”), increased the size of the Board from six to seven directors and unanimously agreed to extend an offer to Dara Richardson-Heron, M.D., to serve as a Class III director of the Company.
On September 24, 2021, the Board of Directors (the “Board”) of Caribou Biosciences, Inc., a Delaware corporation (the “Company”), increased the size of the Board from five to six directors and unanimously agreed to extend an offer to Ran Zheng to serve as a Class I director of the Company, which offer Ms. Zheng accepted on September 24, 2021.
Max materiality 0.85 · Median 0.65 · Most common event other_material